We are live on ! Find out more
Victory Capital Management

Victory Capital Management Portfolio holdings

AUM $156B
1-Year Est. Return 27.51%
This Fund
S&P 500
This Quarter Est. Return
+3.36%
1 Year Est. Return
+27.51%
3 Year Est. Return
+75.53%
5 Year Est. Return
+102.92%
10 Year Est. Return
+480.77%
AUM
$42.7B
AUM Growth
+$713M
Cap. Flow
-$1.02B
Cap. Flow %
-2.39%
Top 10 Hldgs %
6.08%
Holding
1,876
New
75
Increased
1,071
Reduced
591
Closed
69

Sector Composition

Rank Sector Weight
1 Financials 18.6%
2 Industrials 14.61%
3 Technology 14.32%
4 Consumer Discretionary 10.63%
5 Healthcare 9.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ADMS
1726
DELISTED
Adamas Pharmaceuticals
ADMS
$25K ﹤0.01%
1,438
+25
+2% +$413
NVEE
1727
DELISTED
NV5 Global
NVEE
$24K ﹤0.01%
2,304
AXAS
1728
DELISTED
Abraxas Petroleum Corp
AXAS
$24K ﹤0.01%
749
+13
+2% +$488
SGYP
1729
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$22K ﹤0.01%
5,015
+86
+2% +$355
SIMO icon
1730
Silicon Motion
SIMO
$7.11B
$21K ﹤0.01%
435
-118,740
-100% -$5.88M
MLNX
1731
DELISTED
Mellanox Technologies, Ltd.
MLNX
$21K ﹤0.01%
478
SKT icon
1732
Tanger
SKT
$4.78B
$20K ﹤0.01%
765
-30
-4% -$853
CLLS
1733
Cellectis
CLLS
$288M
$18K ﹤0.01%
+683
New +$16.3K
CLVS
1734
DELISTED
Clovis Oncology, Inc.
CLVS
$18K ﹤0.01%
189
-21,204
-99% -$1.3M
CDTX
1735
DELISTED
Cidara Therapeutics
CDTX
$17K ﹤0.01%
110
+2
+2% +$276
LCNB icon
1736
LCNB Corp
LCNB
$289M
$17K ﹤0.01%
865
STML
1737
DELISTED
Stemline Therapeutics, Inc.
STML
$17K ﹤0.01%
+1,858
New +$15.5K
RNR icon
1738
RenaissanceRe
RNR
$13.8B
$16K ﹤0.01%
+114
New +$16K
ACGN
1739
DELISTED
Aceragen Inc
ACGN
$16K ﹤0.01%
69
+1
+1% +$261
WRI
1740
DELISTED
Weingarten Realty Investors
WRI
$16K ﹤0.01%
535
-30
-5% -$958
OLBK
1741
DELISTED
Old Line Bancshares, Inc.
OLBK
$16K ﹤0.01%
+582
New +$16.2K
CIM
1742
Chimera Investment
CIM
$1.06B
$15K ﹤0.01%
+275
New +$15.9K
CRIS icon
1743
Curis
CRIS
$9.71M
$15K ﹤0.01%
4
DVAX
1744
DELISTED
Dynavax Technologies
DVAX
$15K ﹤0.01%
1,557
+27
+2% +$175
ACAD icon
1745
Acadia Pharmaceuticals
ACAD
$4.51B
$14K ﹤0.01%
513
+9
+2% +$268
AGEN
1746
Agenus
AGEN
$276M
$14K ﹤0.01%
188
+3
+2% +$211
HAIN icon
1747
Hain Celestial
HAIN
$44.6M
$14K ﹤0.01%
361
WPM icon
1748
Wheaton Precious Metals
WPM
$49.7B
$14K ﹤0.01%
698
ESPR
1749
DELISTED
Esperion Therapeutics
ESPR
$13K ﹤0.01%
282
+5
+2% +$184
PK icon
1750
Park Hotels & Resorts
PK
$3.08B
$13K ﹤0.01%
+484
New +$12.8K

Similar funds

Victory Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Victory Capital Management held 1,876 positions worth $42.7B, up 1.7% from $42B the previous quarter. Its ten largest holdings account for 6.1% of the portfolio.

Victory Capital Management's Q2 2017 filing shows 75 new, 1,071 increased, 591 reduced and 69 closed positions. Its largest new stake was DXC Technology: 2,390,939 shares worth $159M. The largest sale was Pinnacle Foods, Inc., an estimated $120M.

By sector, the portfolio is most concentrated in Financials at 19% of assets, up from 18% a quarter earlier, followed by Industrials and Technology.

  • Victory Capital Management's largest Q2 2017 buy was DXC Technology: 2,390,939 shares worth $159M.
  • Victory Capital Management added most to Fidelity National Financial in Q2 2017, an estimated $169M increase.
  • Victory Capital Management's biggest Q2 2017 reduction was Pinnacle Foods, Inc., cutting an estimated $120M.
  • Victory Capital Management fully exited Computer Sciences in Q2 2017, selling an estimated $112M.
  • Victory Capital Management's ten largest holdings make up 6.1% of its $42.7B portfolio in Q2 2017.
  • Victory Capital Management opened 75 new positions and closed 69 in Q2 2017.
  • Victory Capital Management's portfolio value rose 1.7% quarter-over-quarter to $42.7B.

Based on Victory Capital Management's 13F filing for Q2 2017, filed 7 Aug 2017.